- Peer-reviewed trials have not flagged serious safety issues, and efficacy is inconsistent across populations, but not in the direction supplement critics usually assume[1]
- The largest trial in cognitively impaired people — 328 patients, 24 weeks, randomized, double-blind and placebo-controlled — found no significant difference from placebo on its primary or secondary outcomes[2]
- Shellfish allergy is the single most concrete safety caution, since most commercial plasmalogens are scallop-derived[3]
- The trial in young adults was financially supported by the Japanese Plasmalogen Society, with the test substance supplied by a commercial partner, which is a funding relationship worth knowing about whichever way the result went[1]
Plasmalogen supplements are marketed heavily on the promise of sharper memory and better mood in aging brains. Search for real complaints, though, and you find something different than the typical “gave me a headache” supplement gripe. The negative signal here is mostly about the supplement not doing much for a meaningful slice of users, not about it causing harm.
The Efficacy Problem Hiding Behind “Safe”
The most rigorous trial in a young, healthy population is worth reading carefully, because it is often described backwards. It randomized 40 male university athletes aged 18 to 22 to 2 mg/day of scallop-derived plasmalogen or placebo for 4 weeks[1]. Its primary outcome was mood, not cognition: the Profile of Mood States total score improved more on plasmalogen, but the between-group difference was only marginal (P=0.07). Two individual mood scales did separate clearly, with anger-hostility at P=0.003 and fatigue-inertia at P=0.005. On the Uchida-Kraepelin test, a marker of mental concentration, the plasmalogen group performed significantly better than placebo.
So the honest caveat for a buyer is not that this trial found nothing. It is that the trial was four weeks long, ran in 40 young male athletes, used 2 mg/day rather than the 1 mg used in the cognitive-decline trials, and measured mood and concentration rather than memory. None of that supports a memory claim in an aging brain, which is what these products are actually marketed on.
Worth flagging directly: this same study was funded by the Japanese Plasmalogen Society, which received donations from the manufacturer of the plasmalogen tested[1]. That doesn’t invalidate the data, but it’s the kind of funding relationship every objective supplement review should disclose rather than bury.
The Largest Trial in the Population Most Likely to Benefit Was Null
The largest and most rigorous trial ever run in this population is also the least quoted by product pages, and the reason is not hard to guess. It randomized 328 patients aged 60 to 85 with mild Alzheimer’s disease or mild cognitive impairment to 1 mg/day of scallop-derived purified plasmalogen or placebo for 24 weeks, double-blind, across multiple centres; 276 completed. In the intention-to-treat analysis covering both mild AD and MCI, no significant difference was shown between the treatment and placebo groups on the primary or secondary outcomes[2]. The primary outcome was the Mini Mental State Examination.
That is not the whole picture, and it would be just as dishonest to stop there. Within the mild AD patients, Wechsler Memory Scale-Revised scores improved in the treatment group, with the between-group difference falling just short of significance (P=0.067), and reaching significance in two subgroups: women (P=0.017) and patients under 77 (P=0.029)[2]. Subgroup findings in a trial whose main analysis was null are a reason to run another trial, not a reason to buy anything. This trial was also funded by the Japanese Plasmalogen Society, the same body that funded the young-adult trial above. No severe adverse events occurred in either group.
A note on a study you will still see quoted. An open-label study of 22 cognitively impaired people, published in 2022 and widely cited on supplement pages for its cognition and mobility breakdown, was retracted by its journal on 13 August 2026, following an Expression of Concern issued on 30 January 2026[4]. An earlier version of this article described that paper as carrying only an Expression of Concern, which was accurate when written and is no longer accurate. A retracted paper cannot support a claim in either direction, so its numbers have been removed from this page rather than reframed. If you encounter a review citing a 2022 Frontiers in Cell and Developmental Biology supplementation trial in cognitively impaired adults — whether to praise plasmalogens or to criticize them — it is citing withdrawn work. Our companion piece on plasmalogen trials in mild cognitive impairment covers the studies that still stand.
What Users Actually Report as Side Effects
Consumer health sites converge on a short, mild list: possible digestive discomfort and mild allergic reactions, with the standard advice to discontinue and consult a doctor if either shows up[3]. No dedicated consumer-complaint threads or a pattern of serious adverse events turned up in the available research or review literature — which is itself worth stating plainly rather than manufacturing drama where the evidence doesn’t support it.
The One Concrete Safety Flag: Shellfish
Because most plasmalogen supplements are derived from scallops, anyone with a shellfish or scallop allergy has a real reason to avoid this category entirely, not a theoretical one[3]. This is the single most actionable caution in the research, and it’s the one most likely to get buried under vague “consult your doctor” boilerplate on product pages.
FAQ
Do plasmalogen supplements have serious side effects?
No serious adverse events have been reported in published trials. Mild digestive discomfort and allergic reactions (especially in people with shellfish allergies) are the documented concerns[3].
Do plasmalogen supplements actually improve memory?
No trial has shown a clear memory benefit in the way these products are marketed. The trial in young male athletes improved mood scales and a concentration measure, but did not test memory[1]. The largest trial in cognitively impaired adults — 328 patients, randomized and placebo-controlled over 24 weeks — found no significant difference from placebo on its primary or secondary outcomes in the intention-to-treat analysis, with memory gains appearing only in mild-AD subgroups[2]. A 2022 open-label study often quoted on this question was retracted by its journal in August 2026 and no longer counts toward the evidence base[4].
Who should avoid plasmalogen supplements?
Anyone with a shellfish or scallop allergy, since most commercial products are scallop-derived[3].
References
- PMC. Orally Administered Plasmalogens Alleviate Negative Mood States and Enhance Mental Concentration: A Randomized, Double-Blind, Placebo-Controlled Trial. pmc.ncbi.nlm.nih.gov/articles/PMC9203127/…
- Fujino T et al. Efficacy and Blood Plasmalogen Changes by Oral Administration of Plasmalogen in Patients with Mild Alzheimer’s Disease and Mild Cognitive Impairment: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. EBioMedicine (2017). PMID 28259590
- ConsumerLab. Plasmalogen Supplements – Safety & Effectiveness. www.consumerlab.com/answers/do-plasmalogens-i…
- RETRACTED. Goodenowe DB et al. Targeted Plasmalogen Supplementation: Effects on Blood Plasmalogens, Oxidative Stress Biomarkers, Cognition, and Mobility in Cognitively Impaired Persons. Frontiers in cell and developmental biology (2022). Retracted by the journal on 13 August 2026, following an Expression of Concern issued on 30 January 2026. Retraction notice: PMID 42662445. Retracted original: PMID 35874835
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
